Teva announced the reintroduction of Leucovorin Calcium for Injection, which has been on shortage due to manufacturing delays.

RELATED: Oncology Resource Center

Leucovorin Calcium, a folic acid derivative, is indicated for rescue after high-dose methotrexate therapy in osteosarcoma; to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists; in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible; and for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.

Leucovorin Calcium for Injection is available in a 350mg/vial strength. As of June 2013, Teva’s 100mg/vial strength is still on supply shortage due to manufacturing delays.

For more information call (888) 838-2872 or visit